RTP Mobile Logo
A Conversation with the Investigators: Endometrial and Cervical Cancers (Faculty Presentations)
Released September 2021

Featuring slide presentations and related discussion from Drs Mansoor Raza Mirza, David O'Malley and Angeles Alvarez Secord. Published September 9, 2021. (Faculty Presentations)

CE Disclosures and Faculty Information

    This program is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of gynecologic cancers.


    • Review available data with anti-PD-1/PD-L1 antibodies for patients with microsatellite instability (MSI)-high and microsatellite-stable recurrent endometrial cancer, and appreciate ongoing research attempting to define the role of these agents in the treatment of this disease.
    • Consider the FDA approval of pembrolizumab in combination with lenvatinib for patients with advanced endometrial cancer that is not MSI high or mismatch repair deficient (dMMR) who have experienced disease progression after systemic therapy, in order to optimally integrate this novel regimen into clinical management algorithms.
    • Recognize the recent FDA approval of dostarlimab for patients with dMMR advanced endometrial cancer after disease progression on or after a prior platinum-based regimen.
    • Appraise available and emerging research findings supporting the use of immune checkpoint inhibitors for progressive advanced cervical cancer, and identify patients appropriate for treatment with these agents in or outside of a clinical research study.
    • Consider emerging pivotal research findings with and the potential clinical role of tisotumab vedotin in therapy for recurrent cervical cancer.
    • Design and implement a plan of care to recognize and manage side effects and toxicities associated with immune checkpoint inhibitors in the management of endometrial and cervical cancer in order to support quality of life and continuation of therapy.
    • Recall the design of ongoing clinical trials evaluating novel agents and strategies for patients with endometrial and cervical cancer, and counsel appropriate individuals about availability and participation.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    Research To Practice designates this enduring material for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ASCOEndoCervical21/Presentations/CME.

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

    Mansoor Raza Mirza, MD
    Medical Director
    Nordic Society of Gynaecological Oncology – Clinical Trial Unit
    Chairman, European Network of Gynaecological Trial Groups
    Faculty Member, European Society of Gynaecological Oncology
    Chief Oncologist
    Copenhagen University Hospital
    Copenhagen, Denmark

    Advisory Committee: Karyopharm Therapeutics, Sera Prognostics; Global Clinical Lead: ENGOT-OV16/NOVA niraparib, ENGOT-EN6/NSGO-RUBY; Institutional Financial Interests (Study Grants): AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Clovis Oncology, Pfizer Inc, Tesaro, A GSK Company, Ultimovacs; Personal Financial Interests: AstraZeneca Pharmaceuticals LP, BIOCAD, Clovis Oncology, Geneos Therapeutics, Genmab, Karyopharm Therapeutics, Merck, Merck Sharp & Dohme Corp, Mersana Therapeutics, Oncology Venture, Pfizer Inc, Roche Laboratories Inc, Seagen Inc, Sera Prognostics, SOTIO LLC, Takeda Oncology, Tesaro, A GSK Company, Zai Lab.

    David M O'Malley, MD
    Division Director, Gynecologic Oncology
    Co-Director, Gynecologic Oncology Phase I Program
    The Ohio State University and The James Cancer Center
    Columbus, Ohio

    Advisory Committee and Consulting Agreements (Personal Fees): AbbVie Inc, Agenus Inc, Ambry Genetics, Amgen Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Elevar Therapeutics, Genentech, a member of the Roche Group, GOG Foundation Inc, ImmunoGen Inc, Iovance Biotherapeutics, Janssen Biotech Inc, Johnson & Johnson Pharmaceuticals, Merck, Mersana Therapeutics, Myriad Genetic Laboratories Inc, Novartis, Novocure Inc, Regeneron Pharmaceuticals Inc, Rubis, Seagen Inc, Tarveda Therapeutics, Tesaro, A GSK Company; Contracted Research (All Funding to Institution): AbbVie Inc, Agenus Inc, Ajinomoto Co Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Daré Bioscience, Eisai Inc, EMD Serono Inc, Ergomed Plc, Genentech, a member of the Roche Group, Genmab, GOG Foundation Inc, ImmunoGen Inc, Iovance Biotherapeutics, Janssen Biotech Inc, Johnson & Johnson Pharmaceuticals, Ludwig Institute for Cancer Research Ltd, Merck, National Cancer Institute, New Mexico Cancer Care Alliance, Novocure Inc, PRA Health Sciences, Regeneron Pharmaceuticals Inc, Seagen Inc, Stemcentrx, Syneos Health, Tesaro, A GSK Company, TRACON Pharmaceuticals Inc, VentiRx Pharmaceuticals Inc, Yale University; Contracted Research (Personal Fees): Clovis Oncology, Mersana Therapeutics; Data and Safety Monitoring Board/Committee: Watermark Research Partners Inc.

    Angeles Alvarez Secord, MD, MHSc
    Professor of Obstetrics and Gynecologist, Gynecologic Oncology
    Director of Gynecologic Oncology Clinical Trials
    Duke Cancer Institute
    Durham, North Carolina

    Advisory Committee (Honorarium): Myriad Genetic Laboratories Inc; Advisory Committee (Uncompensated): AbbVie Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Regeneron Pharmaceuticals Inc, Tesaro, A GSK Company; Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Clovis Oncology, Eisai Inc, Genentech, a member of the Roche Group, Merck, Seagen Inc, Tesaro, A GSK Company; Clinical Trial Steering Committee (Uncompensated): F Hoffmann-La Roche Ltd and Genentech, a member of the Roche Group, for the AtTEnd trial.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc and Verastem Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, GlaxoSmithKline, ImmunoGen Inc and Merck.

    Release date: September 2021
    Expiration date: September 2022

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch video
(WIFI is recommended for best performance):